Kailera Therapeutics — Third Quarter 2026 Earnings Summary

Kailera Therapeutics reported a net loss of $95.7 million for the third quarter ended September 30, 2026, driven by increased research and development expenses of $84.7 million. The company maintains a cash position of $1,037.6 million, providing a runway into mid-2028 to support its clinical pipeline. Key program updates include the full enrollment of the KaiNETIC global Phase 3 trial for ribupatide injection and the ribupatide oral Phase 2b trial, with data expected in mid-2028 and mid-2027, respectively. Additionally, the global Phase 2 trial for safiglipron is fully enrolled with data anticipated in mid-2027, while the IND for KAI-4729 is active with plans to initiate a Phase 1 trial by the end of 2026.